择捷美（重组人粒细胞刺激因子-sndz）：首个获美国食品药品监督管理局批准的生物类似药。
Zarxio (Filgrastim-sndz): The First Biosimilar Approved by the FDA.
作者信息
Awad Mina, Singh Pavit, Hilas Olga
出版信息
P T. 2017 Jan;42(1):19-23.
Abstract
Zarxio (filgrastim-sndz), a biosimilar for the treatment of severe chronic neutropenia.
摘要
择捷美（重组人粒细胞刺激因子-sndz），一种用于治疗严重慢性中性粒细胞减少症的生物类似药。
相似文献
1
2
Totality of the evidence at work: The first U.S. biosimilar.工作中的全部证据：首个美国生物类似药。
Expert Opin Biol Ther. 2016;16(2):137-42. doi: 10.1517/14712598.2016.1128410. Epub 2015 Dec 23.
3
Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.美国生物类似药非格司亭-sndz、参比非格司亭、聚乙二醇化非格司亭以及配备体内注射器的聚乙二醇化非格司亭预防化疗引起的（发热性）中性粒细胞减少症的成本效益分析。
J Med Econ. 2017 Oct;20(10):1083-1093. doi: 10.1080/13696998.2017.1358173. Epub 2017 Aug 4.
4
Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.培非格司亭体注射笔故障导致的发热性中性粒细胞减少症住院治疗与单次注射培非格司亭和参照及生物类似物注射用粒细胞集落刺激因子每日注射相比：肺癌和非霍奇金淋巴瘤的美国成本模拟。
J Med Econ. 2020 Jan;23(1):28-36. doi: 10.1080/13696998.2019.1658591. Epub 2019 Sep 3.
5
Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage.商业保险和医疗保险优势计划中，类人生长因子 Filgrastim 的利用率和费用。
Health Aff (Millwood). 2019 Nov;38(11):1887-1892. doi: 10.1377/hlthaff.2019.00253.
6
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.生物类似药 Filgrastim（复瑞赛/复达欣）的安全性特征：III 期研究的综合分析。
Oncologist. 2018 Apr;23(4):403-409. doi: 10.1634/theoncologist.2017-0348. Epub 2018 Jan 9.
7
Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States.择捷美（重组人粒细胞刺激因子-sndz）：首个在美国获批的生物类似药。
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):150-4.
8
Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.将注射用非格司亭生物类似药转换为中性粒细胞减少症预防疗法，增加癌症治疗的可及性。
Future Oncol. 2017 Oct;13(25):2285-2295. doi: 10.2217/fon-2017-0374. Epub 2017 Sep 5.
9
Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.生物类似物非格司亭（Zarzio®）预防化疗引起的（发热性）中性粒细胞减少症的起始时间为“同日”（<24 小时）、“按指南”（24-72 小时）和“延迟”（>72 小时）：来自 MONITOR-GCSF 研究的结果。
Support Care Cancer. 2019 Jun;27(6):2301-2312. doi: 10.1007/s00520-018-4513-6. Epub 2018 Oct 20.
10
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.EP2006（一种非格司亭生物类似药）与参比制剂交替治疗预防乳腺癌患者接受骨髓抑制化疗后发生重度中性粒细胞减少症的安全性和有效性：一项 III 期、随机、双盲临床研究。
Ann Oncol. 2018 Jan 1;29(1):244-249. doi: 10.1093/annonc/mdx638.
引用本文的文献
1
Biosimilars: A Critical Review of Development, Regulatory Landscape, and Clinical Implications.生物类似药：对其研发、监管环境及临床意义的批判性综述
AAPS PharmSciTech. 2025 Jan 27;26(1):46. doi: 10.1208/s12249-025-03038-2.
2
Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation.培非格司亭生物类似药在接受大剂量美法仑和自体造血干细胞移植后的多发性骨髓瘤患者中的疗效。
Ann Hematol. 2023 Jul;102(7):1915-1925. doi: 10.1007/s00277-023-05228-z. Epub 2023 Apr 20.
3
Oncology biosimilars: New developments and future directions.肿瘤生物类似药：新进展与未来方向。
Cancer Rep (Hoboken). 2022 Nov;5(11):e1720. doi: 10.1002/cnr2.1720. Epub 2022 Oct 4.
4
Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products.生物类似物格利司他汀供应与生物格利司他汀产品的理赔支付和患者自付费用变化之间的关联。
Value Health. 2020 Dec;23(12):1599-1605. doi: 10.1016/j.jval.2020.06.014. Epub 2020 Oct 23.
5
Does use of biosimilar G-CSF change plerixafor utilization during stem cell mobilization for autologous stem cell transplant?在自体干细胞移植的干细胞动员过程中，使用生物类似物粒细胞集落刺激因子（G-CSF）是否会改变普乐沙福的使用情况？
Bone Marrow Transplant. 2020 Aug;55(8):1655-1657. doi: 10.1038/s41409-019-0744-5. Epub 2019 Nov 18.
6
A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation.一项单中心、回顾性分析比较了 filgrastim-sndz 与 filgrastim 预防化疗引起的中性粒细胞减少症和自体干细胞移植后中性粒细胞恢复的疗效和安全性。
Support Care Cancer. 2018 Mar;26(3):1013-1016. doi: 10.1007/s00520-017-3923-1. Epub 2017 Oct 8.
本文引用的文献
1
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.培非格司亭生物类似药EP2006与参比制剂的比较：一项在接受骨髓抑制性化疗的乳腺癌患者中预防严重中性粒细胞减少症的III期随机双盲临床研究。
Ann Oncol. 2015 Sep;26(9):1948-1953. doi: 10.1093/annonc/mdv281. Epub 2015 Jun 28.
Zotero 插件